Author

Mark D. Kochenderfer

Observed names: M. Kochenderfer, M.D. Kochenderfer, Mark Kochenderfer

Observed institutions: Virginia Energy, Carilion Clinic

OpenAlex ID: A5018419601

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

2023 · Robin Kate Kelley, Makoto Ueno, et al. · The Lancet · 1,157

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

2023 · Sun Young Rha, Sun Young Rha, et al. · The Lancet Oncology · 689

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

2021 · David F. McDermott, Jae-Lyun Lee, et al. · Journal of Clinical Oncology · 131

PDF

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

2020 · Nicholas J. Vogelzang, Mark R. Olsen, et al. · Clinical Genitourinary Cancer · 107

PDF

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

2014 · A. Jimeno, K. Shirai, et al. · Annals of Oncology · 98

PDF

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

2024 · Akihito Kawazoe, Rui-Hua Xu, et al. · Journal of Clinical Oncology · 94

PDF

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

2024 · Heinz-Josef Lenz, Aparna Parikh, et al. · Journal for ImmunoTherapy of Cancer · 74

PDF

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.

2022 · Heinz-Josef Lenz, Aparna Raj Parikh, et al. · Journal of Clinical Oncology · 61

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

2025 · Hani M. Babiker, Vincent Picozzi, et al. · Journal of Clinical Oncology · 48

PDF

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma

2016 · Daniel W. Bowles, Mark Kochenderfer, et al. · Clinical Colorectal Cancer · 41

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

2020 · Joshua J. McFarlane, Mark D. Kochenderfer, et al. · Clinical Genitourinary Cancer · 33

A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.

2022 · Thomas Adam Abrams, Syed Mohammad Ali Kazmi, et al. · Journal of Clinical Oncology · 20

Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.

2019 · Nicholas J. Vogelzang, Joshua Jemison McFarlane, et al. · Journal of Clinical Oncology · 16

Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.

2020 · David F. McDermott, Jae-Lyun Lee, et al. · Journal of Clinical Oncology · 14

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.

2020 · David F. McDermott, Jae-Lyun Lee, et al. · Journal of Clinical Oncology · 9

Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8.

2019 · Josep Tabernero, Takayuki Yoshino, et al. · Journal of Clinical Oncology · 5

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

2026 · Robert J Motzer, Robert J Motzer, et al. · The Lancet · 4

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.

2025 · Vincent Chung, Mark D. Kochenderfer, et al. · Journal of Clinical Oncology · 4

PDF

Isolated central nervous system relapse in acute myeloid leukemia: a case report and review of therapeutic challenges

2025 · Colin Burns, Ian Muir, et al. · Frontiers in Oncology · 3

Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).

2017 · David R. Fogelman, Johanna C. Bendell, et al. · Journal of Clinical Oncology · 2

Enhancing a low-cost, minimally invasive screening test for dihydropyrimidine dehydrogenase mutations linked to 5-fluorouracil sensitivity by integrating computational mutation predictions.

2025 · John M Janiga, Dzenis Mahmutovic, et al. · Journal of Clinical Oncology · 1

Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).

2015 · David R. Fogelman, Mark D. Kochenderfer, et al. · Journal of Clinical Oncology · 1

Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial

2026 · Makoto Ueno, Makoto Ueno, et al. · EClinicalMedicine

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study

2026 · D.F. McDermott, S. Signoretti, et al. · Annals of Oncology

Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).

2026 · Cathy Eng, Elena Elez, et al. · Journal of Clinical Oncology

Works count: 29

Citation count: 2,609

H-index: 14

I10-index: 14